NCT07695311 — Rabi Hanna cancer immunotherapy trial
EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT
Registry record
| Registry ID | NCT07695311 ↗ |
|---|---|
| Lead sponsor | Rabi Hanna |
| Collaborators | The Little Warriors Foundation |
| Phase | Phase 1 |
| Status | Not Yet Recruiting |
| Indication | Ewing Sarcoma, Desmoplastic Small Round Cell Tumor |
| Enrollment | 24 participants (target) |
| Start date | 2026-10 |
| Primary completion | 2029-10 (est.) |
| Last registry update | 31 Aug 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07695311), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.
Related trials
FAQ
What phase is NCT07695311?
NCT07695311 (EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT) is registered on ClinicalTrials.gov as Phase 1, sponsored by Rabi Hanna.
Is NCT07695311 recruiting?
As of the 2026-08-31 registry update, NCT07695311 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07695311?
The lead sponsor is Rabi Hanna. Collaborators: The Little Warriors Foundation.
What condition does NCT07695311 study?
The registered conditions are Ewing Sarcoma, Desmoplastic Small Round Cell Tumor. Primary completion is listed as 2029-10 (estimated).
Are results available for NCT07695311?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07695311.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.